Artwork

Content provided by Pri-Med. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pri-Med or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Tirzepatide: A New Treatment for Diabetes - Frankly Speaking Ep 285

11:00
 
Share
 

Manage episode 334643414 series 1338191
Content provided by Pri-Med. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pri-Med or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285

Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.

Episode resource links:

  • Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.

Guest: Alan Ehrlich MD, FAAFP
Music Credit: Richard Onorato

  continue reading

389 episodes

Artwork
iconShare
 
Manage episode 334643414 series 1338191
Content provided by Pri-Med. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Pri-Med or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285

Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus.

Episode resource links:

  • Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11.

Guest: Alan Ehrlich MD, FAAFP
Music Credit: Richard Onorato

  continue reading

389 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide